Menu
← Oncology Approval Tracker
FDA DECISION ·
Carvykti
ciltacabtagene autoleucel · Janssen Biotech / Legend Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory multiple myeloma after at least four previous lines, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
LAMPGEN ANALYSIS
Why it matters
The initial BCMA CAR T-cell approval was for a heavily pretreated population.
What research teams should watch
Reconstruct prior lines and agent classes before planning leukapheresis and bridging therapy.
PRIMARY RECORDS